Patent directory · USPTO A61K / A61P
Patents matching “CRISPR THERAPEUTICS AG”
77 pharma patents match "CRISPR THERAPEUTICS AG" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 77 pharmaceutical patents matching "CRISPR THERAPEUTICS AG" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 11135247
Materials and methods for engineering cells and uses thereof in immuno-oncology
granted -
US 11116798
Universal donor cells
granted -
US 11116797
Universal donor cells
granted -
US 11118177
Materials and methods for treatment of Usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)
granted -
US 11118195
Universal donor cells
granted -
US 11118196
Universal donor cells
granted -
US 11104918
Universal donor cells
granted -
US 11083799
Materials and methods for treatment of hereditary haemochromatosis
granted -
US 11072792
Materials and methods for treatment of usher syndrome type 2A
granted -
US 11071755
Materials and methods for engineering cells and uses thereof in immuno-oncology
granted -
US 11013767
Materials and methods for engineering cells and uses thereof in immuno-oncology
granted -
US 10995328
Materials and methods for treatment of autosomal dominant cone-rod dystrophy
granted -
US 10881689
Materials and methods for engineering cells and uses thereof in immuno-oncology
granted -
EP 3752616
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR GENEDITIERUNG DURCH TARGETING VON FIBRINOGEN-ALPHA
granted -
US 2020384125
GENE EDITING FOR HEMOPHILIA A WITH IMPROVED FACTOR VIII EXPRESSION
granted -
US 10857184
Materials and methods for engineering cells and uses thereof in immuno-oncology
granted -
EP 3728594
MATERIALIEN UND VERFAHREN ZUR BEHANDLUNG DES USHER-SYNDROMS TYP 2A
granted -
US 2020318108
MATERIALS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 2A AND/OR NON-SYNDROMIC AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA (ARRP)
granted -
US 10736919
Materials and methods for engineering cells and uses thereof in immuno-oncology
granted -
US 10729725
Materials and methods for engineering cells and uses thereof in immuno-oncology
granted -
CA 3121191
CAS9 DE CODAGE D'ARNM OPTIMISE DESTINE A ETRE UTILISE DANS DES LNP
granted -
US 10662425
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
granted -
CA 3118090
COMPOSITIONS ET PROCEDES POUR EDITION DU GENOME A MEDIATION PAR NHEJ
granted -
CA 3116885
COMPOSITIONS ET METHODES D'ADMINISTRATION DE TRANSGENE
granted